 |
인쇄하기
취소
|
Strong results seen for combination hypertensive drugs in March
Ubist said recently that combination hypertensive medicines showed strong performances last month on rising demand.
Sales of Novartis’s Exforge (amlodipine plus valsartan) rose 19.7 percent to 5.9 billion won in March, compared to the same period last year.
Astra Zeneca’s Atacand (candesartan) also showed a steady growth with 5.7 billion won in sales.
Boehringer Ingelheim’s Twynsta (am...
Sales of Novartis’s Exforge (amlodipine plus valsartan) rose 19.7 percent to 5.9 billion won in March, compared to the same period last year.
Astra Zeneca’s Atacand (candesartan) also showed a steady growth with 5.7 billion won in sales.
Boehringer Ingelheim’s Twynsta (am...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.